
Collaboration aims to develop targeted, effective cancer immunotherapies
Immunai has joined forces with Baylor College of Medicine to bring more targeted and effective cancer therapies to market. Leveraging Immunai’s single-cell technology and artificial intelligence, Baylor and Immunai will analyse natural killer T (NKT) cells and genetically engineer them into immunotherapies that target a variety of cancers, including solid… Read More



